Atropine sulfate effects on aviator performance and on respiratory-heart period interactions.
In this study, 20 human volunteers received a placebo and atropine doses of 0.5, 1.0, 2.0, and 4.0 mg X 75 kg-1 in a Latin Square double blind design, and effects were monitored for 3 h postinjection. The 2.0 mg and the 4.0 mg doses resulted in significant flight simulator performance decrements beginning at 1 h postinjection with only minimal recovery by 3 h postinjection. Electrocardiogram data were used to estimate the amplitude of respiratory sinus arrhythmia (RSA) which was more sensitive than mean heart period or mean heart period variance to the effects of atropine. These parasympathetic effects were relatively rapid in onset and peaked within the first 40-min period for the 2.0 and 4.0 mg doses. The onset of performance effects were delayed 1 h 40 min for the 2.0 mg and 1 h 00 min for the 4.0 mg treatment.
D000328:Adult; D000337:Aerospace Medicine; D001285:Atropine / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006321:Heart / Q000502:physiology*; D006801:Humans; D011597:Psychomotor Performance / Q000187:drug effects*; D012119:Respiration / Q000187:drug effects*
D001285:Atropine